Kymera Therapeutics (KYMR) Expected to Release Earnings on Wednesday

Kymera Therapeutics (NASDAQ:KYMR) is expected to be issuing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to announce earnings of ($0.7126) per share and revenue of $32.7760 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:30 AM ET.

Kymera Therapeutics Price Performance

Kymera Therapeutics stock traded up $3.93 during midday trading on Tuesday, hitting $104.24. 112,419 shares of the company were exchanged, compared to its average volume of 738,542. The company has a market cap of $8.57 billion, a PE ratio of -29.26 and a beta of 1.95. Kymera Therapeutics has a fifty-two week low of $36.65 and a fifty-two week high of $130.05. The company’s fifty day moving average price is $99.34 and its 200-day moving average price is $87.95.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on KYMR shares. Royal Bank Of Canada lowered shares of Kymera Therapeutics from an “outperform” rating to a “sector perform” rating and lifted their price objective for the company from $106.00 to $115.00 in a research note on Monday, July 13th. Bank of America raised their price target on shares of Kymera Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Mizuho boosted their price objective on shares of Kymera Therapeutics from $120.00 to $140.00 and gave the stock an “outperform” rating in a report on Thursday, July 16th. Truist Financial raised their target price on Kymera Therapeutics from $116.00 to $136.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Finally, Wall Street Zen upgraded Kymera Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 2nd. Twenty equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $124.48.

Insider Buying and Selling

In other Kymera Therapeutics news, Director Bruce Booth sold 467,878 shares of Kymera Therapeutics stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $110.29, for a total value of $51,602,264.62. Following the completion of the transaction, the director directly owned 472,267 shares in the company, valued at $52,086,327.43. The trade was a 49.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Nello Mainolfi sold 80,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $115.29, for a total value of $9,223,200.00. Following the transaction, the chief executive officer directly owned 666,568 shares of the company’s stock, valued at $76,848,624.72. This trade represents a 10.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 3,607,813 shares of company stock valued at $387,818,004. 15.98% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Los Angeles Capital Management LLC acquired a new position in Kymera Therapeutics during the 4th quarter worth $153,000. CIBC Asset Management Inc bought a new position in shares of Kymera Therapeutics in the fourth quarter worth $229,000. Hudson Bay Capital Management LP acquired a new position in shares of Kymera Therapeutics during the second quarter valued at $218,000. Oxford Asset Management LLP acquired a new position in shares of Kymera Therapeutics during the second quarter valued at $201,000. Finally, Lazard Asset Management LLC bought a new stake in shares of Kymera Therapeutics during the second quarter valued at about $116,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.